SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
Author Contributions
Funding
Conflicts of Interest
References
- Focosi, D.; Spezia, P.G.; Maggi, F. Fixation and reversion of mutations in the receptor-binding domain of SARS-COV-2 spike protein. Diagn. Microbiol. Infect. Dis. 2023, 116104. [Google Scholar] [CrossRef]
- Starr, T.N.; Greaney, A.J.; Hilton, S.K.; Ellis, D.; Crawford, K.H.D.; Dingens, A.S.; Navarro, M.J.; Bowen, J.E.; Tortorici, M.A.; Walls, A.C.; et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 2020, 182, 1295–1310.e20. [Google Scholar] [CrossRef] [PubMed]
- NextStrain SARS-CoV-2. Available online: https://next.nextstrain.org/staging/nextclade/sars-cov-2/21L?f_Nextclade_pango=BA.2.86,BQ.1.1,EG.5.1,FL.1.5.1,XBB.1.5&gmin=15&l=scatter&scatterX=ace2_binding&scatterY=immune_escape&showBranchLabels=all (accessed on 19 October 2023).
- Wang, Q.; Guo, Y.; Liu, L.; Schwanz, L.T.; Li, Z.; Ho, J.; Zhang, R.M.; Iketani, S.; Yu, J.; Huang, Y.; et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. bioRxiv 2023. [Google Scholar] [CrossRef]
- Yang, S.; Yu, Y.; Jian, F.; Song, W.; Yisimayi, A.; Chen, X.; Xu, Y.; Wang, P.; Wang, J.; Yu, L.; et al. Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 2023. [Google Scholar] [CrossRef] [PubMed]
- Qu, P.; Xu, K.; Faraone, J.N.; Goodarzi, N.; Zheng, Y.-M.; Carlin, C.; Bednash, J.S.; Horowitz, J.C.; Mallampalli, R.K.; Saif, L.J.; et al. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants. bioRxiv 2023. [Google Scholar] [CrossRef]
- Tracking BA.2.86* Lineage over Time. Raj Rajnarayanan Tableau. Available online: https://public.tableau.com/app/profile/raj.rajnarayanan/viz/TrackingBA_2_86LineageOverTime/BA_2_86. (accessed on 19 October 2023).
- Uriu, K.; Ito, J.; Kosugi, Y.; Tanaka, Y.L.; Mugita, Y.; Guo, Z.; Hinay, A.A., Jr.; Putri, O.; Kim, Y.; Shimizu, R.; et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 2023. [Google Scholar] [CrossRef]
- Khan, K.; Lustig, G.; Reedoy, K.; Jule, Z.; Römer, C.; Karim, F.; Ganga, Y.; Bernstein, M.; Baig, Z.; Mahlangu, B.; et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. medRxiv 2023. [Google Scholar] [CrossRef]
- Lassauniere, R.; Polacek, C.; Baig, S.; Ellegaard, K.; Escobar-Herrera, L.A.; Fomsgaard, A.; Spiess, K.; Schwartz, O.; Planas, D.; Simon-Loriere, E.; et al. Neutralisation of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies induced by earlier infection or vaccination. bioRxiv 2023. [Google Scholar] [CrossRef]
- Wang, X.; Jiang, S.; Ma, W.; Li, X.; Wei, K.; Xie, F.; Zhao, C.; Zhao, X.; Li, C.; Qiao, R.; et al. Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster. bioRxiv 2023. [Google Scholar] [CrossRef]
- An, Y.; Zhou, X.; Tao, L.; Xie, H.; Li, D.; Wang, R.; Hu, H.; Xu, Z.; Dai, L.; Xu, K.; et al. SARS-CoV-2 Omicron BA.2.86: Less neutralization evasion compared to XBB sub-variants. bioRxiv 2023. [Google Scholar] [CrossRef]
- Hu, Y.; Zou, J.; Kurhade, C.; Deng, X.; Chang, H.C.; Kim, D.K.; Shi, P.-Y.; Ren, P.; Xie, X. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. bioRxiv 2023. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, D.J.; Franchini, M.; Joyner, M.J.; Casadevall, A.; Focosi, D. Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources. Nat. Commun. 2022, 13, 6478. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, D.J.; Franchini, M.; Senefeld, J.W.; Joyner, M.J.; Casadevall, A.; Focosi, D. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB. J. Gen. Virol. 2023. [Google Scholar] [CrossRef] [PubMed]
- Sheward, D.J.; Yang, Y.; Westerberg, M.; Öling, S.; Muschiol, S.; Sato, K.; Peacock, T.P.; Hedestam, G.B.K.; Albert, J.; Murrell, B. Sensitivity of BA.2.86 to prevailing neutralising antibody responses. bioRxiv 2023. [Google Scholar] [CrossRef]
- Lasrado, N.; Collier, A.-r.Y.; Hachmann, N.P.; Miller, J.; Rowe, M.; Schonberg, E.D.; Rodrigues, S.L.; LaPiana, A.; Patio, R.C.; Anand, T.; et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.2.86. bioRxiv 2023. [Google Scholar] [CrossRef]
- Chalkias, S.; McGhee, N.; Whatley, J.L.; Essink, B.; Brosz, A.; Tomassini, J.E.; Girard, B.; Wu, K.; Edwards, D.K.; Nasir, A.; et al. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines. medRxiv 2023. [Google Scholar] [CrossRef]
- Pfizer Says Updated COVID Shot Gneerated Strong Reaction Versus New Variant in Mice. Available online: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-updated-covid-shot-generated-strong-reaction-vs-new-variant-mice-2023-09-06/ (accessed on 20 September 2023).
- SARS-CoV-2 Variant Surveillance and Assessment: Technical Briefing 53 Updated 14 September 2023. Available online: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings/sars-cov-2-variant-surveillance-and-assessment-technical-briefing-53 (accessed on 20 September 2023).
- Reeve, L.; Tessier, E.; Trindall, A.; Abdul Aziz, N.I.B.; Andrews, N.; Futschik, M.; Rayner, J.; Didier’Serre, A.; Hams, R.; Groves, N.; et al. High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023. Eurosurveillance 2023, 28, 2300489. [Google Scholar] [CrossRef]
- Rasmussen, M.; Møller, F.T.; Gunalan, V.; Baig, S.; Bennedbæk, M.; Christiansen, L.E.; Cohen, A.S.; Ellegaard, K.; Fomsgaard, A.; Franck, K.T.; et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Eurosurveillance 2023, 28, 2300460. [Google Scholar] [CrossRef]
- Meo, S.A.; Meo, A.S.; Klonof, D.C. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics a global data-based analysis. Eur. Rev. Med. Pharmacol. Sci. 2023, 27, 9470–9476. [Google Scholar] [CrossRef]
- Focosi, D. A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance. Viruses 2023, 15, 1048. [Google Scholar] [CrossRef]
- He, Q.; Wu, L.; Xu, Z.; Wang, X.; Xie, Y.; Chai, Y.; Zheng, A.; Zhou, J.; Qiao, S.; Huang, M.; et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep. Med. 2023, 4, 100991. [Google Scholar] [CrossRef] [PubMed]
- Yamasoba, D.; Uriu, K.; Plianchaisuk, A.; Kosugi, Y.; Pan, L.; Zahradnik, J.; Ito, J.; Sato, K. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect. Dis. 2023, 23, 655–656. [Google Scholar] [CrossRef] [PubMed]
- Wannigama, D.L.; Amarasiri, M.; Phattharapornjaroen, P.; Hurst, C.; Modchang, C.; Chadsuthi, S.; Anupong, S.; Miyanaga, K.; Cui, L.; Fernandez, S.; et al. Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. Lancet Infect. Dis. 2023. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Focosi, D.; Spezia, P.G.; Maggi, F. SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage? Vaccines 2023, 11, 1634. https://doi.org/10.3390/vaccines11111634
Focosi D, Spezia PG, Maggi F. SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage? Vaccines. 2023; 11(11):1634. https://doi.org/10.3390/vaccines11111634
Chicago/Turabian StyleFocosi, Daniele, Pietro Giorgio Spezia, and Fabrizio Maggi. 2023. "SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?" Vaccines 11, no. 11: 1634. https://doi.org/10.3390/vaccines11111634
APA StyleFocosi, D., Spezia, P. G., & Maggi, F. (2023). SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage? Vaccines, 11(11), 1634. https://doi.org/10.3390/vaccines11111634